Table 5.
Treatment switching for each osteoporosis treatment group and database
| Database | Switching | ALN | OBP | IVBP | DENO | TERI | SERMS |
|---|---|---|---|---|---|---|---|
| CPRD GOLD (UK) | 6 months | 149 (2.3) | 8 (1.0) | 0 (0) | 0 (0) | NA | 0 (0) |
| 12 months | 22 (0.3) | 6 (0.7) | 0 (0) | 0 (0) | NA | 0 (0) | |
| 18 months | 10 (0.2) | < 5 | 0 (0) | 0 (0) | NA | 0 (0) | |
| 24 months | < 5 | < 5 | 0 (0) | < 5 | NA | 0 (0) | |
| CPRD AURUM (UK) | 6 months | 3,545 (2.6) | 514 (2.5) | 17 (0.9) | 110 (0.8) | 5 (0.9) | 15 (2.5) |
| 12 months | 834 (0.6) | 189 (0.9) | 10 (0.5) | 62 (0.5) | 0 (0) | 5 (0.8) | |
| 18 months | 334 (0.2) | 94 (0.5) | 13 (0.7) | 19 (0.1) | 0 (0) | 7 (1.2) | |
| 24 months | 149 (0.1) | 30 (0.1) | 0 (0) | 12 (< 0.1) | 0 (0) | < 5 | |
| HSD (IT) | 6 months | 243 (1.9) | 123 (1.8) | < 5 | 23 (0.7) | 15 (2.2) | < 5 |
| 12 months | 76 (0.6) | 36 (0.5) | 0 (0) | 25 (0.7) | 7 (1.0) | 0 (0) | |
| 18 months | 32 (0.2) | 19 (0.3) | 0 (0) | 6 (0.2) | 13 (1.9) | < 5 | |
| 24 months | 15 (0.1) | 7 (0.1) | 0 (0) | < 5 | 16 (2.3) | 0 (0) | |
| IPCI (NL) | 6 months | 469 (4.1) | 120 (3.0) | < 5 | 17 (0.7) | < 5 | 0 (0) |
| 12 months | 126 (1.1) | 49 (1.2) | < 5 | 12 (0.5) | 0 (0) | 0 (0) | |
| 18 months | 65 (0.6) | 13 (0.3) | < 5 | 9 (0.4) | 0 (0) | < 5 | |
| 24 months | 11 (< 0.1) | 7 (0.2) | 0 (0) | < 5 | < 5 | 0 (0) | |
| NDR (DK) | 6 months | 2,364 (4.3) | 207 (6.7) | 252 (1.0) | 115 (1.1) | 82 (4.2) | 6 (8.0) |
| 12 months | 676 (1.2) | 65 (2.1) | 166 (0.7) | 85 (0.8) | 39 (2.0) | < 5 | |
| 18 months | 252 (0.5) | 31 (1.0) | 147 (0.6) | 65 (0.6) | 31 (1.6) | < 5 | |
| 24 months | 118 (0.2) | 17 (0.6) | 50 (0.2) | 44 (0.4) | 114 (5.8) | 0 (0) | |
| SIDIAP (ES) | 6 months | 999 (2.3) | 248 (3.8) | NA | 139 (0.8) | 138 (3.8) | 52 (3.4) |
| 12 months | 417 (1.0) | 82 (1.3) | NA | 88 (0.5) | 62 (1.7) | 41 (2.7) | |
| 18 months | 247 (0.6) | 56 (0.9) | NA | 62 (0.3) | 41 (1.1) | 20 (1.3) | |
| 24 months | 141 (0.3) | 29 (0.4) | NA | 51 (0.3) | 87 (2.4) | 24 (1.6) | |
| GePaRD (DE) | 6 months | 2,444 (4.6) | 720 (5.1) | 31 (1.3) | 154 (0.9) | 46 (4.3) | 48 (4.4) |
| 12 months | 335 (0.6) | 136 (1.0) | 16 (0.7) | 99 (0.6) | 15 (1.4) | 15 (1.4) | |
| 18 months | 134 (0.3) | 55 (0.4) | 18 (0.7) | 34 (0.2) | 11 (1.0) | 8 (0.7) | |
| 24 months | 16 (< 0.1) | 8 (< 0.1) | < 5 | 12 (< 0.1) | 5 (0.5) | < 5 |
Results presented in numbers (percentages) and masked when patient counts were less than five
ALN: alendronate; DENO: denosumab; IVBP: intravenous bisphosphonates; NA: not available;
OBP: other oral bisphosphonates; SERM: selective estrogen receptor modulators; TERI: teriparatide
DE: Germany; DK: Denmark; ES: Spain; IT: Italy; NL: The Netherlands; UK: United Kingdom